![[Congrès] 3ème journée probiotiques et microbiotes intestinal – 4 February – Lyon](/images/Congres/01_MICROBIOTE_WEB.png "[Congrès] 3ème journée probiotiques et microbiotes intestinal – 4 February – Lyon")
« At the forefront of precision medicine using microbiota signature »
It is now known that the human microbiota, which consists of a wide variety of microorganisms, plays a much larger role in human health and disease than previously assumed. Even if the causality is not always established, a microbial imbalance or dysbiosis has been reported in several diseases. It includes cancer, colitis, atopic dermatitis, diabetes, liver and lung fibrosis, multiple sclerosis, etc.
Oncodesign has developed models for pathologies related to microbiota disorders and therefore can customize studies for programs from preclinical to early clinical phases.
Our thorough technologic and scientific knowledge in various therapeutic areas i.e. oncology, inflammatory and infectious diseases, allow us to support the development of microbiota-based therapies.
The influence of the microbiota on the effectiveness of cancer treatments, such as immunotherapies, has begun to be widely characterized in humans.
It allowed the identification of beneficial or harmful bacteria and so to diagnostic or predictive drug efficacy biomarkers.
In this context, different approaches can be conceived to shape the gut microflora in order to reestablish anti-cancer immune responses in murine cancer models:
- probiotics that are products favoring the proliferation and function of beneficial bacterial species,
- probiotics – it consist of single or mixtures of live bacterial species - a category that can also include bacteriophages i.e viruses that kill bacteria with high target specificity-
- fecal material transplant (autologous or allogeneic).
I want to know more about your expertise
%MCEPASTEBIN
![[Congress] Innovation for Health – Rotterdam, The Netherlands – 13 February](/images/Congres/Innovation_Health_Web.png "[Congress] Innovation for Health – Rotterdam, The Netherlands – 13 February")